National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 4491-4492 [2019-02424]

Download as PDF khammond on DSKBBV9HB2PROD with NOTICES Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices 4491 DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Institutes of Health National Institute of Mental Health; Notice of Closed Meetings Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings Name of Committee: National Institute of Mental Health Special Emphasis Panel; NIMH Clinical Trials: Effectiveness of Treatment, Preventive, and Services Interventions. Date: April 1, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Monaco, 700 F Street NW, Washington, DC 20001. Contact Person: Karen Gavin-Evans, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Boulevard, Room 6153, MSC 9606, Bethesda, MD 20892, 301–451–2356, gavinevanskm@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01). Date: April 2, 2019. Time: 12:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center Building, (NSC) 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Rebecca Steiner Garcia, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6149, MSC 9608, Bethesda, MD 20892–9608, 301–443–4525, steinerr@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 16– 121: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK. Date: March 15, 2019. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Antonello Pileggi, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6166, Bethesda, MD 20892–7892, (301) 402–6297, pileggia@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 16– 121: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK. Date: March 15, 2019. Time: 6:00 p.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Elaine Sierra-Rivera, Ph.D., Scientific Review Officer, EMNR IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6182, MSC 7892, Bethesda, MD 20892, 301 435– 2514, riverase@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 11, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. Dated: February 9, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–02477 Filed 2–14–19; 8:45 am] [FR Doc. 2019–02406 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P VerDate Sep<11>2014 19:41 Feb 14, 2019 Jkt 247001 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of meetings of the Division of Intramural Research Board of Scientific Counselors, NIAID. The meetings will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Allergy and Infectious Diseases, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Division of Intramural Research Board of Scientific Counselors, NIAID. Date: June 10–12, 2019. Time: 8:00 a.m. to 10:00 a.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, Building 50, 50 Center Drive, Bethesda, MD 20892. Contact Person: Steven M Holland, MD, Ph.D., Chief, Laboratory of Clinical Infectious Diseases, National Institutes of Health/ NIAID, Hatfield Clinical Research Center, Bethesda, MD 20892–1684, 301–402–7684, sholland@mail.nih.gov. Name of Committee: Division of Intramural Research Board of Scientific Counselors, NIAID. Date: December 9–11, 2019. Time: 10:00 a.m. to 10:00 a.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health 50, 50 Center Drive, Bethesda, MD 20892. Contact Person: Steven M Holland, MD, Ph.D., Chief, Laboratory of Clinical Infectious Diseases, National Institutes of Health/ NIAID, Hatfield Clinical Research Center, Bethesda, MD 20892–1684, 301–402–7684, sholland@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, E:\FR\FM\15FEN1.SGM 15FEN1 4492 Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: February 11, 2019. Natasha Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–02424 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: ‘‘Treatment of Acute Lymphoblastic Leukemia, T-Cell Lymphoma, and Non-Small Cell Lung Cancer Using the 4A10 Antibody and Fragments Thereof’’ AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to Fannin Partners L.L.C., (‘‘Fannin’’) of Houston, Texas. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before March 4, 2019 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Lauren Nguyen-Antczak, Sr. Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm. 1E530, MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702 Telephone: (240)–276–5530; Facsimile: (240)-276–5504 Email: lauren.nguyen-antczak@nih.gov. SUPPLEMENTARY INFORMATION: khammond on DSKBBV9HB2PROD with NOTICES SUMMARY: Intellectual Property Entitled ‘‘IL–7R-alpha Specific Antibodies for Treating Acute Lymphoblastic Leukemia’’ (1) U.S. Provisional Patent Application No. 62/238,612, filed October 7, 2015, corresponding to NIH Ref. No. E–247–2015/0–US–0; (2) International Patent Application No. PCT/US2016/055957, filed October 7, 2016, corresponding to NIH Ref. No. E–247–2015/0–PCT–02; VerDate Sep<11>2014 19:41 Feb 14, 2019 Jkt 247001 (3) Australian Patent Application No. 2016–335750, filed October 7, 2016, corresponding to NIH Ref. No. E–247– 2015/0–AU–03; (4) Canadian Patent Application No. 2997809, filed October 7, 2016, corresponding to NIH Ref. No. E–247– 2015/0–CA–04; (5) European Patent Application No. 16784678.1, filed October 7, 2016, corresponding to NIH Ref. No. E–247– 2015/0–EP–05; (6) U.S. Patent Application No. 15/ 760,193, filed March 14, 2018, corresponding to NIH Ref. No. E–247– 2015/0–US–07; The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be where patent applications are filed and the field of use may be limited to ‘‘Treatment of acute lymphoblastic leukemia, T-cell lymphoma, and non-small cell lung cancer using the 4A10 antibody and fragments thereof’’. Additional licensable fields of use are available. The subject technology is directed to monoclonal antibodies (mAb) specific for the alpha chain of the interleukin 7 receptor (IL–7Ra), and corresponding antigen binding fragments, bispecific antibodies, antibody drug conjugates, and encoding nucleic acid thereof. Specifically developed mAbs include those called ‘‘4A10’’ and ‘‘2B8’’. In certain embodiments, the 4A10 antibody can be administered to treat acute lymphoblastic leukemia, particularly those that arise from aberrations in T-cell lineages. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 Freedom of Information Act, 5 U.S.C. 552. Dated: February 6, 2019. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2019–02442 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of The Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: June 13, 2019. Time: 9:00 a.m. to 5:30 p.m. Agenda: NIH Director’s Report, ACD Working Group Reports, Other Business of the Committee. Place: National Institutes of Health, Natcher Building, Conference Room D, 45 Center Drive, Bethesda, MD 20892. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: June 14, 2019. Time: 9:00 a.m. to 1:00 p.m. Agenda: ACD Working Group Reports, Other Business of the Committee. Place: National Institutes of Health, Natcher Building, Conference Room D, 45 Center Drive, Bethesda, MD 20892. Contact Person: Gretchen Wood, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive, Building 1, Room 126, Bethesda, MD 20892, 301–496–4272, Woodgs@od.nih.gov. Name of Committee: Advisory Committee to the Director, National Institutes of Health Date: December 12, 2019. Time: 9:00 a.m. to 5:30 p.m. Agenda: NIH Director’s Report, ACD Working Group Reports, Other Business of the Committee. Place: National Institutes of Health, Natcher Building, Conference Room D, 45 Center Drive, Bethesda, MD 20892. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: December 13, 2019. Time: 9:00 a.m. to 1:00 p.m. Agenda: ACD Working Group Reports, Other Business of the Committee. E:\FR\FM\15FEN1.SGM 15FEN1

Agencies

[Federal Register Volume 84, Number 32 (Friday, February 15, 2019)]
[Notices]
[Pages 4491-4492]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02424]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of meetings of the Division of 
Intramural Research Board of Scientific Counselors, NIAID.
    The meetings will be closed to the public as indicated below in 
accordance with the provisions set forth in section 552b(c)(6), Title 5 
U.S.C., as amended for the review, discussion, and evaluation of 
individual intramural programs and projects conducted by the National 
Institute of Allergy and Infectious Diseases, including consideration 
of personnel qualifications and performance, and the competence of 
individual investigators, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: Division of Intramural Research Board of 
Scientific Counselors, NIAID.
    Date: June 10-12, 2019.
    Time: 8:00 a.m. to 10:00 a.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: National Institutes of Health, Building 50, 50 Center 
Drive, Bethesda, MD 20892.
    Contact Person: Steven M Holland, MD, Ph.D., Chief, Laboratory 
of Clinical Infectious Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center, Bethesda, MD 20892-1684, 
301-402-7684, sholland@mail.nih.gov.

    Name of Committee: Division of Intramural Research Board of 
Scientific Counselors, NIAID.
    Date: December 9-11, 2019.
    Time: 10:00 a.m. to 10:00 a.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: National Institutes of Health 50, 50 Center Drive, 
Bethesda, MD 20892.
    Contact Person: Steven M Holland, MD, Ph.D., Chief, Laboratory 
of Clinical Infectious Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center, Bethesda, MD 20892-1684, 
301-402-7684, sholland@mail.nih.gov.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856,

[[Page 4492]]

Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: February 11, 2019.
Natasha Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-02424 Filed 2-14-19; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.